Sie können Operatoren mit Ihrer Suchanfrage kombinieren, um diese noch präziser einzugrenzen. Klicken Sie auf den Suchoperator, um eine Erklärung seiner Funktionsweise anzuzeigen.
Findet Dokumente, in denen beide Begriffe in beliebiger Reihenfolge innerhalb von maximal n Worten zueinander stehen. Empfehlung: Wählen Sie zwischen 15 und 30 als maximale Wortanzahl (z.B. NEAR(hybrid, antrieb, 20)).
Findet Dokumente, in denen der Begriff in Wortvarianten vorkommt, wobei diese VOR, HINTER oder VOR und HINTER dem Suchbegriff anschließen können (z.B., leichtbau*, *leichtbau, *leichtbau*).
Safety and efficacy of bone marrow mononuclear cell therapy for ischemic stroke recovery: a systematic review and meta-analysis of randomized controlled trials
Cell-based therapy represents a potential treatment for ischemic stroke (IS). Here, we performed a systematic review and meta-analysis to summarize the evidence provided by randomized controlled trials (RCTs) for the transplantation of bone marrow mononuclear cells (BMMNCs) in patients with IS in any phase after stroke.
Methods
We searched several databases for relevant articles up to the 10th of March 2023, including MEDLINE, EMBASE, the Cochrane Library, and ClinicalTrials.gov. Subgroup analyses were implemented to evaluate the dose and route of BMMNC administration. Statistical data were analyzed by Review Manager version 5.3 software.
Results
Six RCTs were included in this article, including 177 patients who were treated by the transplantation of BMMNCs and 166 patients who received medical treatment. The three-month National Institutes of Health Stroke Scale (NIHSS) score indicated a favorable outcome for the BMMNC transplantation group (standardized mean difference (SMD), − 0.34; 95% confidence interval (CI), − 0.57 to − 0.11; P = 0.004). There were no significant differences between the two groups at six months post-transplantation with regards to NIHSS score (SMD 0.00; 95% CI − 0.26 to 0.27; P = 0.97), modified Rankin Scale (risk ratio (RR) 1.10; 95% CI 0.75 to 1.63; P = 0.62), Barthel Index change (SMD 0.68; 95% CI − 0.59 to 1.95; P = 0.29), and infarct volume change (SMD − 0.08; 95% CI − 0.42 to 0.26; P = 0.64). In addition, there was no significant difference between the two groups in terms of safety outcome (RR 1.24; 95% CI 0.80 to 1.91; P = 0.33).
Conclusion
Our meta-analysis demonstrated that the transplantation of BMMNCs was safe; however, the efficacy of this procedure requires further validation in larger RTCs.
Yanbing Tang and Zilan Wang contribute equally to this work.
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Introduction
Stroke is the second leading cause of death worldwide and a major cause of disability [1]. The lifetime risk of stroke in individuals over the age of 25 years is estimated to be 24.9% globally; of those experiencing stroke, the risk of ischemic stroke (IS) is 18.3% [2]. When suffering a stroke, cerebral blood vessels become blocked due to the formation of blood clots. This can lead to cerebral edema and cerebral infarction, causing irreversible damage to neurological function and seriously affecting a patient’s prognosis [3].
Early treatments, such as intravenous thrombolysis and arterial embolization, have been shown to significantly reduce the mortality and disability rate after suffering acute IS although the time window for treatment is restricted to only 6 to 8 h [4‐6]. In the subacute to chronic phases of IS, treatment strategies may be adjusted depending upon an individual patient’s condition. These strategies may include the management of cholesterol, antithrombotic medications, and rehabilitation training; however, these methods are associated with limited efficacy in the promotion of functional recovery [7]. IS largely considered to have a poor prognosis, and no therapies have been proven to treat this condition effectively. However, the advancement of cell transplantation technology has provided a new avenue for the management of IS in the acute, subacute, or chronic phase [8].
Anzeige
Cell-based therapies for stroke emerged in the 1990s and are widely considered to represent a potential treatment for IS [9, 10]. Cell-based therapy can improve the prognosis of patients with IS by facilitating cell replacement, stimulating endogenous repair processes, promoting brain plasticity and synaptic reorganization, and facilitating immunomodulation [11, 12]. Currently, cell-based therapy research includes the use of different types of cells, such as bone marrow mononuclear cells (BMMNCs), hematopoietic stem cells, neural stem cells, and mesenchymal stem cells; different routes of administration, such as intracerebral, intra-arterial, intravenous, intrathecal, and intranasal; different doses, depending on cell type and the route of administration; and different time windows for treatment, ranging from days to months and years [13]. Of the various cell types, hematopoietic stem cells have been shown to possess only limited ability to differentiate into neurons; neural stem cells have been associated with ethical issues and immune-related problems, and mesenchymal stem cells require several weeks for expansion with conventional culture techniques [14]. BMMNCs offer significant potential since they can be obtained from the patients themselves without expansion and are easy to collect, prepare, and preserve, thus avoiding potential ethical issues or immune-related problems.
BMMNCs represent a heterogeneous mix of hematopoietic progenitor cells, a population of mesenchymal and endothelial precursors [15]. Previous research has demonstrated that these cells have the capacity to protect neurons and reduce the loss of neurons resulting from stroke [16, 17]. The autologous transplantation of BMMNCs has been shown to be efficacious in animal models of stroke by exerting a range of biological effects, including the attenuation of neuronal death, the modulation of microglia, the reduction of proinflammatory responses, the enhancement of neoangiogenesis, and the promotion of endogenous neural stem cell proliferation [18, 19]. The mechanisms aimed at enhancing the outcomes of stroke may differ according to the specific phase of stroke. During the acute phase, BMMNC therapy facilitates neuroprotection mainly by releasing trophic factors, regulating inflammation, and promoting neurorestoration. In the chronic phase, the focus transitions to neurorestoration in patients with a stable chronic deficit [20].
However, the efficacy of BMMNC transplantation remains controversial, and numerous key parameters have yet to be fully determined, including the time window for treatment, dosage, and the route of BMMNC administration. Furthermore, there are no published meta-analyses of randomized controlled trials (RCTs) relating to the transplantation of BMMNCs in patients with IS. Therefore, in the present study, we conducted a meta-analysis to summarize existing evidence for the efficacy and safety of BMMNC transplantation in IS.
Methods
Study protocol
Prior to commencing the project, we drafted a research protocol following the Cochrane Collaboration format [21], which was registered on the INPLASY website (Register number: INPLASY202340061 https://inplasy.com/inplasy-2023-4-0061/).
Anzeige
Eligibility criteria
Our inclusion criteria were as follows: (1) participants (adults diagnosed with IS); (2) intervention (the transplantation of BMMNCs with medical treatment at any phase of IS); (3) comparison group (conventional medical treatment); and (4) outcome (the main outcome was the National Institutes of Health Stroke Scale (NIHSS) score at three months while the secondary outcomes included NIHSS scores at six months, modified Rankin Scale (mRS) scores at six months, Barthel Index (BI) scores at six months, and changes in infarct volume at six months). Safety outcomes included the occurrence of adverse events, including partial seizures, fever, infection, and vascular disorders; and (5) study type: RCT.
Publications were excluded based on the following criteria: (1) case reports, case series, comments, letters, reviews, retrospective studies, prospective studies, or animal experiments, and (2) publications featuring incomplete information or lacking extractable data.
Search strategy
Two dependent investigators (YBT and ZLW) searched MEDLINE, EMBASE, the Cochrane Library, and ClinicalTrials.gov to identify related articles up to the 10th of March 2023. We used a range of keywords (including “stem cell,” “bone marrow mononuclear cell,” and “stroke”) to develop different search strategies for different databases. The detailed search strategies are shown in Table S1.
Quality assessment and data collection
The risk of bias for the included RCTs was assessed by applying the Cochrane Collaboration tool [22]. The quality of the attained outcome was assessed using the GRADEpro Guideline Development Tool. The quality of the articles was independently assessed by two researchers (YBT and ZLW), with differences resolved by a third researcher (HYT). After evaluating and identifying the articles, two authors (HYN and HRC) extracted a range of data from each of the included RCTs, including the name of the first author, year of publication, publication, study region, intervention, the number of included patients, patient age, sex ratio, and outcome events, as summarized in Table 1.
Table 1
Characteristics of the included studies and outcome events
Study
Publications
Countries
Study design
Centers
Regimen
Phase
Treatment group
(no. of participants)
Male (%)
Mean age (years) ± SD
Outcome Events
Moniche
2023
Lancet Neurol
Spain
Open-label, RCT (NCT02178657)
4
Intra-arterial injection of 2 × 106 BMMNCs/kg or 5 × 106 BMMNCs/kg
Acute
BMMNC: 39
Control: 38
BMMNC: 54
Control: 66
BMMNC: 64.46 ± 15.22
Control: 66.0 ± 13.3
a, b, c, e, f
Savitz 2019
Circulation
USA
RCT (NCT01273337)
10
Intra-arterial infusion of 5 × 107 BMMNCs (two cycles)
Subacute
BMMNC: 29
Control: 19
BMMNC: 69
Control: 94
BMMNC: 59.3 ± 10.03
Control: 62. 9 ± 10.81
a, b, d, f
Bhatia 2018
AJNR Am J Neuroradiol
India
Open-label, blinded-end point, RCT
1
Intravenous injection of a maximum of 5 × 108 BMMNCs
Subacute
BMMNC: 10
Control: 10
BMMNC: 80
Control: 60
BMMNC: 57 ± 12.2
Control: 66 ± 7.3
c, f
Jin 2017
Int J Clin Exp Med
China
RCT
1
Subarachnoid injection of 1 × 107 BMMNCs
Chronic
BMMNC: 10
Control: 10
BMMNC: 90
Control: 60
BMMNC: 50.80 ± 17.428
Control: 53.10 ± 13.068
a, b, c, f
Liu 2014
Chinese Journal of Physical Medicine and Rehabilitation
China
RCT
1
Subarachnoid injection of 1 × 107 BMMNCs/kg (four cycles)
Subacute
BMMNC: 29
Control: 29
BMMNC: 62
Control: 69
BMMNC: 55.34 ± 3.63
Control: 56.87 ± 4.39
a, f
Prasad 2014
Stroke
India
Single blinded, RCT (NCT01501773)
5
Intravenous injection of 2.8 × 108 BMMNCs
Subacute
BMMNC: 60
Control: 60
BMMNC: 68
Control: 60
BMMNC: 50.7 ± 11.6
Control: 52.5 ± 12.1
a, b, c, d, e, f
RCT randomized controlled trial, SD standard deviation (year), BMMNC bone marrow mononuclear cell, a 3-mounth NIHSS, b 6-month NIHSS, c 6-month mRS, d 6-mounth BI change, e infarct volume change, f adverse events
Outcome measures
We included the NIHSS score at three months as the primary outcome, NIHSS, mRS, BI score, and infarct volume change at six months as secondary outcomes since they represent the major scales for measuring neurological impairment and the prognosis of stroke. The mRS is used to measure the neurological recovery of stroke patients on a scale of seven points from 0 to 6 [23]. The NIHSS score ranges from 0 to 42 and is used to assess the degree of functional impairment caused by stroke; this consists of a total of 11 tests, with higher scores indicating more severe neurological impairment [24]. The BI scale is used to assess a patient’s ability to perform activities of daily living and can be used to evaluate functional recovery before and after treatment. The BI consists of ten items with a total score of 100; independent ability is positively correlated with the BI score [25]. For the safety endpoint, we analyzed the occurrence of adverse events within each RCT.
Subgroup analysis
We performed subgroup analysis based on the dose and route of administration. After examining the doses of all trials, we defined an injection of ≥ 3 × 106 BMMNCs/kg as a high dose and < 3 × 106 BMMNCs/kg as a low dose. We also categorized the injection methods; three RCTs involved intra-arterial injections [20, 26, 27], one RCT involved intravenous injections [28], and two RCTs involved subarachnoid injections [29, 30].
Statistical analyses
Review Manager version 5.3 software was used to conduct all statistical analyses. For continuous variables, we calculated the standardized mean difference (SMD) and 95% confidence interval (CI). For dichotomous results, we used the risk ratio (RR) with 95% CIs. Cochrane’s Q test and the I2 statistic were calculated to access heterogeneity. A random-effects model was used for data with significant heterogeneity (P ≤ 0.1 and I2 ≥ 50%) while a fixed-effects model was used for data without significant heterogeneity (P > 0.1 and I2 < 50%). A P value < 0.05 was considered to be statistically significant.
Results
Search results and study characteristics
We initially identified 1188 articles from Medline, Embase, the Cochrane Library, and ClinicalTrials.gov. Of these, 430 duplicate articles and 705 articles that were not directly relevant were excluded. After scanning 53 articles, 19 articles were excluded for not retrieved, and 28 articles were excluded because they were in inappropriate formats, including reviews, non-randomized clinical trials, case reports, and letters. Finally, six RCTs [20, 26‐31] were included in our final meta-analysis. Figure 1 shows a flowchart illustrating the process used for literature searches.
Fig. 1
The study search, selection, and inclusion process
The main characteristics of the six included studies are listed in Table 1. Four of the research studies were from Asia (two from China, and two from India) [26, 28‐31], one study was from Spain [20], and one study was from the USA [27]. The six studies included a total of 343 patients;177 patients were transplanted with BMMNCs; and 166 patients received medical treatment.
Efficacy outcome analysis
The primary outcome was the NIHSS score at three months. Five studies reported NIHSS scores at three months; there was a significant difference between the BMMNC transplantation group and the control group (SMD − 0.34; 95% CI − 0.57 to − 0.11; P = 0.004; I2 = 38%; Fig. 2A).
Fig. 2
Meta-analysis of efficacy: A Three-month National Institutes of Health Stroke Scale (NIHSS) score. B Six-month NIHSS score. C Six-month modified Rankin scale (mRS) score. D Six-month Barthel index (BI) score change. E Six-month infarct volume change
The secondary outcomes were the NIHSS score, the mRS score, the change in BI score, and the change in infarct volume at six months. Four studies reported the NIHSS score at six months after the transplantation of BMMNCs; there was no significant difference between the treatment group and the control group (SMD 0.00; 95% CI − 0.26 to 0.27; P = 0.97; I2 = 0%; Fig. 2B). Three studies investigated the number of patients with favorable clinical outcomes (mRS scores ≤ 2) within six months of BMMNC transplantation; there was no significant difference compared to the control group (RR 1.10; 95% CI 0.75 to 1.63; P = 0.62; I2 = 45%; Fig. 2C). There was no significant difference between the control group and the BMMNC transplantation group in terms of the change of BI at six months (SMD 0.68; 95% CI − 0.59 to 1.95; P = 0.29; I2 = 90%; Fig. 2D). There was no significant difference between the BMMNC transplantation group and the control group in terms of the change of infarct volume at six months (SMD − 0.08; 95% CI − 0.42 to 0.26; P = 0.64; I2 = 0%; Fig. 2E).
Safety outcome analysis
With regard to safety outcome, there was no significant difference between the BMMNC transplantation group and the control group in terms of the number of patients experiencing adverse effects, such as fever, infection, seizures, and cardiac disorders (RR 1.24; 95% CI 0.80 to 1.91; P = 0.33; I2 = 0%; Fig. 3).
We also conducted subgroup analysis to investigate the effect of different cell doses and routes of administration. We found no significant difference for different doses in terms of NIHSS score, mRS score, and the change of infarct volume (Table 2). However, in terms of the change in BI score at six months, we observed a significantly better result for low doses of BMMNCs (SMD 1.37; 95% CI 0.64 to 2.11; P = 0.0003; Table 2); however, this result should be interpreted with caution since only one RCT was included in this subgroup. With regard to the route of administration, we observed a more significant effect for the subarachnoid route in terms of the improvement of NIHSS scores at three months after treatment (SMD − 0.73; 95% CI − 1.20 to − 0.27; P = 0.002; I2 = 61%; Table 2). We also identified a more significant effect for the intra-arterial route with respect to the change of BI score at six months (SMD 1.37; 95% CI 0.64 to 2.11; P = 0.0003; Table 2); however, this analysis also included one RCT.
Table 2
Subgroup analysis of outcomes
Efficacy outcomes
Safety outcomes
mRS at six months
NIHSS at three months
NIHSS at six months
BI change at six months
Infarct volume change at six months
Adverse events
RR (95%CI)
P value
SMD (95% CI)
P value
SMD (95% CI)
P value
SMD (95% CI)
P value
SMD (95% CI)
P value
SMD (95% CI)
P value
RR (95%CI)
P value
1. Dose of BMMNCs
High
1.15
(0.64, 2.08)
0.64
N/A
N/A
− 0.37
(− 0.92, 0.18)
0.19
0.19
(− 0.15, 0.53)
0.28
0.08
(− 0.29, 0.44)
0.68*
− 0.12
(− 0.50, 0.26)
0.54
1.02
(0.60, 1.72)
0.95
Low
N/A
N/A
− 0.45
(− 1.59, 0.68)
0.43
− 0.31
(− 0.68, 0.06)
0.10
− 0.05
(− 0.43, 0.32)
0.78
1.37
(0.64, 2.11)
0.0003*
− 0.24
(− 0.79, 0.31)
0.39*
1.59
(0.71, 3.56)
0.26
2. Route of administration
Intra-arterial
1.39
(0.89, 2.16)
0.15
N/A
N/A
− 0.24
(− 0.61, 0.12)
0.19
0.16
(− 0.21, 0.53)
0.39
1.37
(0.64, 2.11)
0.0003*
− 0.20
(− 0.65, 0.26)
0.40*
1.68
(0.76, 3.69)
0.20
Intravenous
0.67
(0.29, 1.51)
0.33*
N/A
N/A
− 0.17
(− 0.57, 0.24)
0.42*
− 0.12
(− 0.54, 0.29)
0.56*
0.08
(− 0.29, 0.44)
0.68*
0.06
− 0.45, 0.57)
0.81*
0.96
(0.56, 1.65)
0.89*
Subarachnoid
N/A
N/A
0.10
(− 0.78, 0.98)
0.83*
− 0.73
(− 1.20, − 0.27)
0.002
− 0.31
(− 1.20, 0.57)
0.49*
N/A
N/A
N/A
N/A
5.00
(0.27, 92.62)
0.28
mRS modified Rankin Scale, NIHSS National Institutes of Health Stroke Scale, BI Barthel index, SMD standardized mean difference, RR risk ratio, CI confidence interval, BMMNC bone marrow mononuclear cells, N/A not applicable
*Only one study was included
Bolded P values indicate statistically significant findings ( P < 0.05)
Risk of bias
Details relating to the risk of bias assessment for the included RCTs are shown in Fig. 4. Despite the assessment results of some articles being unclear, three articles had higher risks in terms of performance bias since they did not use sham injections; this may have resulted in the failure to blind all patients due to the obvious differences between BMMNC transplantation injection and conventional medical therapy. The quality of GRADE evidence is summarized in Table 3. With regard to the NIHSS, mRS, BI, and infarct volume, the quality of evidence varied from low to moderate.
Fig. 4
Risk of bias: a summary table for each risk of bias item for each study
GRADE evidence profile of BMMNCs transplantation in patients with ischemic stroke
Outcomes
Participants (studies)
Overall certainty of evidence
Relative effect (95% CI)
Anticipated absolute effects
Risk with control group
Risk difference with BMMNCs transplantation
3-month NIHSS
294
(5 RCTs)
⨁⨁◯◯ Lowa,b
-
The mean NIHSS was 8.65
SMD 0.34 SD lower
(0.57 lower to 0.11 lower)
6-month NIHSS
224
(4 RCTs)
⨁⨁◯◯ Lowa,b
-
The mean NIHSS was 6.35
SMD 0 SD
(0.26 lower to 0.27 higher)
6-month mRS
192
(3 RCTs)
⨁⨁⨁◯ Moderatea
RR 1.15
(0.64 to 2.08)
286 per 1,000
43 more per 1,000
(103 fewer to 309 more)
6-month BI change
156
(2 RCTs)
⨁⨁⨁◯ Moderateb
-
The mean BI was 31.0
SMD 0.68 SD higher
(0.59 lower to 1.95 higher)
6-month infarct volume change
133
(2 RCTs)
⨁⨁⨁◯ Moderateb
-
The mean infarct volume change was 15.68
SMD 0.08 SD lower
(0.42 lower to 0.26 higher)
CI confidence interval, SMD standardized mean difference, RCT randomized clinical trial, RR risk ratio, BMMNC bone marrow mononuclear cell, NIHSS National Institutes of Health Stroke Scale, mRS modified Rankin Scale, BI Barthel Index
aRisk of selection and performance bias within studies
bPresence of heterogeneity between studies
Discussion
We conducted a meta-analysis related to the treatment of IS with BMMNC transplantation based on six RCTs. Our study demonstrated that the transplantation of BMMNCs resulted in a statistically significant improvement in NIHSS scores at three months when compared with control groups. In addition, the transplantation of BMMNCs did not increase the incidence of adverse effects. However, no statistically significant differences were observed in terms of NIHSS scores, mRS scores, BI scores, or changes in infarct volume, when compared between the BMMNC transplantation group and the control group at six months.
The latest Global Burden of Disease (GBD) 2019 stroke burden reported that the mortality rate of stroke was estimated to be 4.53% [32]. Over the last ten years, the application of cell-based therapy for stroke has advanced from bench to bedside. Among the various categories of cell-based therapies, BMMNCs derived from the patient’s own bone marrow have emerged as a particularly promising method, as evidenced by several studies incorporating animal models [15, 33‐35]. BMMNCs enhance endogenous recovery mechanisms both locally and in distant locations from the infarct, potentially via immunomodulation and the reduction of post-stroke inflammation. Both in vivo and in vitro studies have demonstrated that BMMNCs can inhibit the production of IL-6, IL-1β, and TNF-α by the microglia and the secretion of anti-inflammatory cytokines such as IL-4, IL-10, and TGF-β1 [36‐38]. Central effects involve the release of trophic factors such as cytokines, chemokines, and extracellular vesicles to improve outcomes after IS. Moreover, stem cells can induce angiogenesis and the repair of the blood–brain-barrier (BBB) following IS [39‐42]. Furthermore, BMMNC therapy can play a crucial role in repairing and functionally reconstructing damaged neural circuits [43‐46]. The safety of BMMNCs in stroke patients has been confirmed by several clinical trials [20, 47]. However, the efficacy of BMMNCs remains controversial.
Anzeige
In the present study, analysis of the three-month NIHSS score revealed a favorable result in patients who underwent BMMNC transplantation, indicating a better improvement of the neurological deficit over the short term. Of the five included RCTs, one study reported a significant difference between the BMMNC transplantation group and the control group; the others all showed improved outcomes in the BMMNC transplantation group, although the observed differences were not statistically significant. However, there was no statistically significant difference detected between the two groups at six months after treatment. An RCT conducted on acute IS patients revealed that at six months, the outcome of the BMMNC transplantation group was inferior to that of the control group [20]. The trophic factors and cytokines produced by BMMNCs may accelerate the recovery of IS [20]. Consequently, differences were evident in the first three months, although this impact was less prominent at six months; the mechanisms responsible for these effects remain unclear. With regard to the six-month mRS score and BI score, our findings suggest that BMMNC transplantation has the potential to enhance patient outcomes, although this was not statistically significant. This finding implies that BMMNC transplantation may not significantly improve overall disability, dependence, and activities of daily living when compared to the control group. However, it is important to note that substantial heterogeneity was observed in the BI score between the two included studies. Furthermore, we did not detect a significant difference in infarct volume when compared between the BMMNC transplantation groups and control groups. Prasad et al. [28] observed a reduction of infarct volume in the BMMNC transplantation group, while Moniche et al. [20] did not observe a significant change. Notably, the different baseline infarct volumes between the two trials may lead to different conclusions. Moniche [20] proposed that instead of brain infarct volume, other mechanisms could be used to predict functional outcomes in a more precise manner, such as the restoration of cortical connections between brain hemispheres. Therefore, the recommendation is to utilize advanced magnetic resonance imaging (MRI) techniques, such as diffusion tensor imaging or functional MRI, to validate the hypothesis of enhanced neuroplasticity.
Our meta-analysis revealed a significant change in the BI score with low doses of BMMNC treatment. A recently published multicenter RCT demonstrated that the efficacy of treatment was more prominent in the low-dose group (2 × 106 BMMNCs/kg) when compared to the high-dose group (5 × 106 BMMNCs/kg), with higher BI scores and lower NIHSS scores [20]. However, animal studies have shown that the administration of high doses of cells can increase the efficacy of cell-based therapy in stroke [48‐50]. Yang et al. [50] observed a more effective treatment result when using BMMNCs at doses of 1 × 107 and 3 × 107 cells/kg when compared with 1 × 106 BMMNCs/kg. This discrepancy could be attributed to the high dose employed in clinical trials, which is far less than that used in animal studies. Wang et al. [49] also found no significant difference between groups of animal models of stroke that were implanted with BMMNCs doses ranging from 1 × 106 to 1 × 107 BMMNCs/kg. However, exceeding the optimal threshold for transplanted cells may result in saturation of the damaged striatum, thus leading to a progressive reduction in the survival of transplanted cells due to insufficient nutrients.
With regard to the route of administration, our meta-analysis revealed that the subarachnoid pathway exhibited a greater propensity for improving NIHSS outcome, while the intra-arterial pathway demonstrated greater efficacy in terms of changes in BI score. However, the limited number of RCTs resulted in the inclusion of only a small number of patients in each subgroup, potentially impacting the validity of these findings. Some studies also compared the effect of BMMNC transplantation using intra-arterial and intravenous routes; however, these studies found no significant difference in terms of efficacy outcomes between the two methods [51, 52]. The intravenous route is regarded as the simplest and least invasive technique [53], although a considerable portion of transplanted cells can become trapped in peripheral organs [54, 55]. On the other hand, the intra-arterial route allows for more efficient biological biodistribution by bypassing peripheral filtering organs such as the liver, spleen, and lungs [56]. The subarachnoid route achieved the highest engraftment rate among all administration routes with approximately one-third of the cells still migrating to the ischemic area [57, 58]. As mentioned earlier, during the early stages of IS, BMMNC therapy contributes to functional recovery mainly by releasing trophic factors. Therefore, it is advisable to consider less invasive treatments, such as intra-arterial and intravenous transplantation [59]. However, during the chronic phase of IS, when the acute pathophysiological changes have stabilized, the focus shifts to the replacement of damaged tissue. In this case, the subarachnoid pathway or other invasive routes are more commonly used to directly deliver cells into the central nervous system, thus facilitating the reconstruction of the neural circuit, and the replacement of damaged brain tissues in IS [60, 61]. However, the use of subarachnoid delivery requires careful consideration since subarachnoid routes are associated with several problems, including invasiveness and the risk of intracranial infection [62]. Furthermore, the intranasal and intraperitoneal routes are currently in the preclinical study phase and require more evaluation of their safety and efficacy before being implemented in large-scale clinical trials.
This meta-analysis also has some limitations that need to be considered. Firstly, it should be noted that the sample size of the included RCTs was small; this may have led to reliability deficiencies. In addition, due to the lack of evidence, we did not investigate the optimal timing of BMMNC transplantation in this article. Notably, some RCTs did not use sham injections; furthermore, these trials did not keep participants and observers blinded due to the obvious differences between BMMNC transplantation injection and conventional medical therapy.
Anzeige
Conclusion
Our meta-analysis showed that BMMNCs transplantation was safe, but its validity remains to be certified. In the future, more RCTs with long-term follow-ups are needed to validate the specific efficacy of BMMNC therapy in IS.
Acknowledgements
We appreciate the valuable and constructive suggestions and assistance from our Team of Neurosurgical study.
Declarations
Consent to participate
Not applicable.
Consent for publication
Not applicable.
Anzeige
Competing interests
The authors declare no competing interests.
Ethics approval
We confirm that we have read the Journal’s position on issues involved in ethical publication and affirm that this report is consistent with those guidelines.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Safety and efficacy of bone marrow mononuclear cell therapy for ischemic stroke recovery: a systematic review and meta-analysis of randomized controlled trials
Verfasst von
Yanbing Tang
Zilan Wang
Haiying Teng
Hanyu Ni
Huiru Chen
Jiaye Lu
Zhouqing Chen
Zhong Wang
Wang W, Jiang B, Sun H et al (2017) Prevalence, incidence, and mortality of stroke in China: results from a nationwide population-based survey of 480 687 adults. Circulation 135(8):759–771. https://doi.org/10.1161/circulationaha.116.025250CrossRefPubMed
5.
Emberson J, Lees KR, Lyden P et al (2014) Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials. Lancet (London, England) 384(9958):1929–1935. https://doi.org/10.1016/s0140-6736(14)60584-5CrossRefPubMed
6.
Saver JL, Goyal M, van der Lugt A et al (2016) Time to treatment with endovascular thrombectomy and outcomes from ischemic stroke: a meta-analysis. JAMA 316(12):1279–1288. https://doi.org/10.1001/jama.2016.13647CrossRefPubMed
Powers WJ, Rabinstein AA, Ackerson T et al (2018) 2018 guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 49(3):e46–e110. https://doi.org/10.1161/str.0000000000000158CrossRefPubMed
Borlongan CV, Tajima Y, Trojanowski JQ et al (1998) Transplantation of cryopreserved human embryonal carcinoma-derived neurons (NT2N cells) promotes functional recovery in ischemic rats. Exp Neurol 149(2):310–321. https://doi.org/10.1006/exnr.1997.6730CrossRefPubMed
Kawabori M, Shichinohe H, Kuroda S et al (2020) Clinical trials of stem cell therapy for cerebral ischemic stroke. Int J Molec Sci 21(19):7380. https://doi.org/10.3390/ijms21197380CrossRef
Pollock K, Stroemer P, Patel S et al (2006) A conditionally immortal clonal stem cell line from human cortical neuroepithelium for the treatment of ischemic stroke. Exp Neurol 199(1):143–155. https://doi.org/10.1016/j.expneurol.2005.12.011CrossRefPubMed
Moniche F, Cabezas-Rodriguez JA, Valverde R et al (2023) Safety and efficacy of intra-arterial bone marrow mononuclear cell transplantation in patients with acute ischaemic stroke in Spain (IBIS trial): a phase 2, randomised, open-label, standard-of-care controlled, multicentre trial. Lancet Neurol 22(2):137–146. https://doi.org/10.1016/s1474-4422(22)00526-9CrossRefPubMed
21.
Liberati A, Altman DG, Tetzlaff J et al (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ (Clin Res Ed) 339:b2700. https://doi.org/10.1136/bmj.b2700CrossRef
22.
Higgins JP, Altman DG, Gøtzsche PC et al (2011) The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ (Clin Res ed). 343:d5928. https://doi.org/10.1136/bmj.d5928CrossRef
Bhatia V, Gupta V, Khurana D et al (2018) Randomized assessment of the safety and efficacy of intra-arterial infusion of autologous stem cells in subacute ischemic stroke. AJNR Am J Neuroradiol 39(5):899–904. https://doi.org/10.3174/ajnr.A5586CrossRefPubMedPubMedCentral
27.
Savitz SI, Yavagal D, Rappard G et al (2019) A phase 2 randomized, sham-controlled trial of internal carotid artery infusion of autologous bone marrow-derived ALD-401 cells in patients with recent stable ischemic stroke (RECOVER-Stroke). Circulation 139(2):192–205. https://doi.org/10.1161/circulationaha.117.030659CrossRefPubMed
28.
Prasad K, Sharma A, Garg A et al (2014) Intravenous autologous bone marrow mononuclear stem cell therapy for ischemic stroke: a multicentric, randomized trial. Stroke 45(12):3618–3624. https://doi.org/10.1161/strokeaha.114.007028CrossRefPubMed
29.
Jin Y, Ying L, Yu G et al (2017) Analysis of the long-term effect of bone marrow mononuclear cell transplantation for the treatment of cerebral infarction. Int J Clin Exp Med 10(2):3059–3068
30.
Liu DH, Han BJ, SS. H (2014) Transplanting autologous mesenchymal nerve stem cells in the treatment of cerebral infarction. Chin J Phys Med Rehabil 36:425–428
Zhang LL, Zhang HT, Cai YQ et al (2016) Anti-inflammatory effect of mesenchymal stromal cell transplantation and quercetin treatment in a rat model of experimental cerebral ischemia. Cell Mol Neurobiol 36(7):1023–1034. https://doi.org/10.1007/s10571-015-0291-6CrossRefPubMed
Wang J, Yu L, Jiang C et al (2013) Bone marrow mononuclear cells exert long-term neuroprotection in a rat model of ischemic stroke by promoting arteriogenesis and angiogenesis. Brain Behav Immun 34:56–66. https://doi.org/10.1016/j.bbi.2013.07.010CrossRefPubMed
41.
Muir KW, Bulters D, Willmot M et al (2020) Intracerebral implantation of human neural stem cells and motor recovery after stroke: multicentre prospective single-arm study (PISCES-2). J Neurol Neurosurg Psychiatry 91(4):396–401. https://doi.org/10.1136/jnnp-2019-322515CrossRefPubMed
42.
Wang J, Liu X, Lu H et al (2015) CXCR4(+)CD45(-) BMMNC subpopulation is superior to unfractionated BMMNCs for protection after ischemic stroke in mice. Brain Behav Immun 45:98–108. https://doi.org/10.1016/j.bbi.2014.12.015CrossRefPubMed
Hatakeyama M, Ninomiya I, Otsu Y et al (2020) Cell therapies under clinical trials and polarized cell therapies in pre-clinical studies to treat ischemic stroke and neurological diseases: a literature review. Int J Molec Sci 21(17):6194. https://doi.org/10.3390/ijms21176194CrossRef
45.
Vonderwalde I, Azimi A, Rolvink G et al (2020) Transplantation of directly reprogrammed human neural precursor cells following stroke promotes synaptogenesis and functional recovery. Transl Stroke Res 11(1):93–107. https://doi.org/10.1007/s12975-019-0691-xCrossRefPubMed
46.
Ping S, Qiu X, Kyle M et al (2019) Stem cell factor and granulocyte colony-stimulating factor promote brain repair and improve cognitive function through VEGF-A in a mouse model of CADASIL. Neurobiol Dis 132:104561. https://doi.org/10.1016/j.nbd.2019.104561CrossRefPubMed
Wang LQ, Lin ZZ, Zhang HX et al (2014) Timing and dose regimens of marrow mesenchymal stem cell transplantation affect the outcomes and neuroinflammatory response after ischemic stroke. CNS Neurosci Ther 20(4):317–326. https://doi.org/10.1111/cns.12216CrossRefPubMedPubMedCentral
Zhang HL, Xie XF, Xiong YQ et al (2018) Comparisons of the therapeutic effects of three different routes of bone marrow mesenchymal stem cell transplantation in cerebral ischemic rats. Brain Res 1680:143–154. https://doi.org/10.1016/j.brainres.2017.12.017CrossRefPubMed
54.
Kawabori M, Kuroda S, Sugiyama T et al (2012) Intracerebral, but not intravenous, transplantation of bone marrow stromal cells enhances functional recovery in rat cerebral infarct: an optical imaging study. Neuropathology 32(3):217–226. https://doi.org/10.1111/j.1440-1789.2011.01260.xCrossRefPubMed
Darsalia V, Kallur T, Kokaia Z (2007) Survival, migration and neuronal differentiation of human fetal striatal and cortical neural stem cells grafted in stroke-damaged rat striatum. Eur J Neurosci 26(3):605–614. https://doi.org/10.1111/j.1460-9568.2007.05702.xCrossRefPubMed
58.
De Feo D, Merlini A, Laterza C et al (2012) Neural stem cell transplantation in central nervous system disorders: from cell replacement to neuroprotection. Curr Opin Neurol 25(3):322–333. https://doi.org/10.1097/WCO.0b013e328352ec45CrossRefPubMed
Kalladka D, Sinden J, Pollock K et al (2016) Human neural stem cells in patients with chronic ischaemic stroke (PISCES): a phase 1, first-in-man study. Lancet (London, England) 388(10046):787–796. https://doi.org/10.1016/s0140-6736(16)30513-xCrossRefPubMed
Fällt ein Bluttest auf pTau im Alter von 60 Jahren positiv aus, blieben noch rund 21 Jahre bis zum Beginn einer Demenz. 70-Jährige haben noch 17 Jahre Zeit, 90-Jährige nur noch 5 Jahre. Darauf deuten Modellrechnungen basierend auf kontinuierlich erhobenen Blutuntersuchungen.
Eine große italienische Studie ermöglicht interessante Einblicke in die zeitliche Dynamik von affektiven Störungen vor Ausbruch einer manifesten Parkinson-Erkrankung (PD). Demnach könnten Angst und Depression unter Umständen schon bis zu zehn Jahre vor der PD auftreten. Zugleich bleiben Fragen.
Gedanken an eine Selbsttötung gehen Ärztinnen und Ärzten vergleichsweise häufig durch den Kopf. Hilfe wäre möglich, wird aber selten gesucht. Warum eigentlich?
Ärzte und Psychotherapeuten mit einem neuen Heilberufsausweis der Generation 2.1 müssen diesen jetzt mitunter nochmals tauschen. Die KBV appelliert an die Betroffenen, der Aufforderung ihres Anbieters nachzukommen und umgehend eine Austauschkarte zu beantragen.
